Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. - Wikidata - wikimedia - TriplyDB

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

http://www.wikidata.org/entity/Q35031732

about

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Selection and expansion of natural killer cells for NK cell-based immunotherapy NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity In vivo monitoring of natural killer cell trafficking during tumor immunotherapy Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report NK cell-based immunotherapy for malignant diseases.Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses.Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine.A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.Present and Future of Allogeneic Natural Killer Cell Therapy Immune microenvironment in tumor progression: characteristics and challenges for therapy Improved Chemotherapeutic Activity by Morus alba Fruits through Immune Response of Toll-Like Receptor 4.A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting Neonatal natural killer cell function: relevance to antiviral immune defense The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.Shaping of NK cell responses by the tumor microenvironment Immunocytokines: a review of molecules in clinical development for cancer therapy.Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.Neutrophils: important contributors to tumor progression and metastasis."NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function.Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.

P2860

Q21131216-2D565321-B078-4C67-BCFA-94276271B544 Q26752780-FB95CDA5-3279-4B3A-A067-85294C939F51 Q26774777-A9CE957B-8D20-4E0C-9F9D-C7D717F1A704 Q26797345-DC889D80-FD52-4ED1-AD79-01E3370A1A55 Q27009908-AD69C1E2-23C4-4B47-9113-ECBB679352FB Q27011245-07533F94-2339-4BA0-92A7-268BAAD8CA65 Q30398870-3EE8565A-CD52-49E4-91F4-748D05F6EDE6 Q33585293-3600F91A-B16E-40D5-8BD3-081C13A8A8E4 Q33748308-8227561A-E346-400A-99CE-F11018EFBB5E Q33827433-D1C15FC7-E13D-40E5-83C3-065B3CEC551F Q34169579-2AD437FB-27C7-4A08-A219-C6FCC3CA6C29 Q34275134-3E2CD40B-2BB1-4148-9FE1-5297A5C0794D Q34548847-AB885C46-A5C1-4B7C-9CE3-DE147C075F0A Q34551581-D5E5701B-2011-4A01-ABF0-0DC86774FD71 Q35154170-0B99FE5E-FC4C-4863-AE65-75F16BF24EB8 Q35542801-F07EDE9E-3CF7-4024-A1EC-838A471ED317 Q35588890-3F21114B-90A1-4CBF-9BBA-596210E9845D Q35677351-532FE48B-EB52-4FBD-A2EB-4ED6E8CEF3AB Q36178400-C96E7A7D-FDDF-4F0E-AADB-C48981EF8643 Q36247376-C5C38165-2CFD-4C63-8C2F-0BAE7F7CC10C Q36547750-C080C947-4782-4BD1-8DCB-B0DC9CCE1DF6 Q36625824-C2A2173D-08C0-4F05-8510-34F5780376AE Q36635664-7DC8F417-3CB3-4E37-8AE2-194F16425E14 Q36856792-A5A7B449-D41D-4619-98B2-E4CAE7BB1A28 Q37138332-DD7D605E-7148-41D2-9B27-68213882BC31 Q37162875-41C80E46-AE9C-4BE0-8178-E31AEFC20E7A Q37413162-78D8F13C-0A35-4306-B815-9F70463797F9 Q37434670-E4AF86E8-F17E-4B9B-B833-96A130DEDF19 Q38067641-BA9A903B-74E4-4A0D-81BF-C639FFD15577 Q38132742-F3998551-59C7-480D-B5FF-5D1ACB575B97 Q38233046-E8AE5534-C4A1-4422-8F8F-D9E548535631 Q38269777-FEE1A6C6-8DCB-4798-8B9D-12C8DDD43130 Q38585102-F28423EF-EFA1-4D80-A8F0-67701D02D2DF Q38723957-223A6D50-1432-4A6B-A267-B91DDE9A3492 Q38772382-347D626D-4470-497D-8EFD-F514B53636B6 Q38831202-A8DF0D98-6986-4041-B178-8F5A597E6A00 Q38912287-5D75669A-6953-4747-AA85-1D228ADF7697 Q38915262-BE56ACA8-EB24-4DEA-91E2-57CC3EB910ED Q38920328-9A24FFB1-7214-46CD-B35C-AC94AC007480 Q38982777-3A4CE935-E405-44EC-8962-A8106D812B9B

P2860

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

http://www.wikidata.org/entity/Q35031732

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

@ast

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

@en

type

label

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

@ast

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

@en

prefLabel

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

@ast

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

@en

P1433

Q35031732-AB69D48C-4B3D-4E73-9B9B-3F2CCAC1DC6E

P1476

Q35031732-1F177AAA-371F-40A8-8C1F-18ACF65AAF57

P2093

Q35031732-1D4724FD-94FC-40AB-B21B-DBB03D5B5E05

Q35031732-24800B85-729C-4E4C-A38E-1BE5D5473E70

P2860

Q35031732-04E7EF57-A105-4A2A-934C-0F1C4DD5F8E7

Q35031732-11914001-D609-49C3-BF79-A6F9F630CC44

Q35031732-11AFCA37-9EF3-4E98-9DE1-1854BE83F801

Q35031732-128484F6-6C71-4A89-924E-0CCB032619D7

Q35031732-1FF9B8B2-6564-44FA-BD0E-DE714F2D6C5B

Q35031732-24F0638F-56A6-4761-8BA7-E267F3E3909A

Q35031732-2C1812C9-C631-4B4A-9F7E-8E127F1DA8C4

Q35031732-2D91FCC5-D81E-4E77-B655-45F76DE70A11

Q35031732-336D8A7C-6BC3-4F8B-A336-785F30BE269C

Q35031732-33C69B06-7841-4BC7-A5F8-31ECA9D1E191

P304

Q35031732-FBBD40CA-1B98-46F8-A875-FB75E0F293F2

P31

Q35031732-442BB3BF-4660-4168-88B9-88A94AC06D69

Q35031732-995358AC-14D8-418B-B82D-D02C56D514C9

P356

Q35031732-1882056C-32D2-4669-BB67-3B8455439417

P478

Q35031732-CA064062-A53B-45EA-A4D3-AC6F646DF812

P577

Q35031732-51BAF4D9-9C71-4A8F-B5CF-625FE2CC228D

P5875

Q35031732-639D9AAE-37E6-471F-81E4-8820C6B0DF46

P698

Q35031732-F0F23595-96BE-4A3F-BC8B-E2936980560E

P921

Q35031732-33D0FFAE-A93C-4CA9-9708-674F8A2AB58F

Q35031732-638E32DE-5BA9-43A4-9333-DAE8AC1759DA

Q35031732-6DA1BCF9-8723-4C47-AE93-8D3DF75165FB

Q35031732-79029FBB-B855-4057-B89A-A827E91AD5D6

Q35031732-A84FFCAC-343F-4951-92AD-A19DD01822A6

Q35031732-AA12927B-C237-4824-AB36-A47271439178

Q35031732-D69D988A-6FFD-4C1D-94E4-CF1FD0702E3B

Q35031732-EA5F4B85-CF23-49ED-9E25-A38B18F086A4

P932

Q35031732-8BFB59C3-8801-48C2-BBA6-66CF8BC2DC2C

P356

P1433

Journal of Biomedicine and Biotechnology

P1476

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

@en

P2093

Kory L Alderson

http://www.w3.org/2001/XMLSchema#string

Paul M Sondel

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

KIR: diverse, rapidly evolving receptors of innate and adaptive immunity

IgG Fc receptors

Fcgamma receptors as regulators of immune responses

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment.

Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment

P304

379123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/379123

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51207562

http://www.w3.org/2001/XMLSchema#string

P698

21660134

http://www.w3.org/2001/XMLSchema#string

P921

monoclonal antibody

hemic and immune systems

P932

3110303

http://www.w3.org/2001/XMLSchema#string